Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Minoxidil and finasteride treat hair loss; more research needed for other options.

The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

Dupilumab for eczema may cause hair loss.

Alopecia Areata has no guaranteed treatment for hair regrowth, but options like corticosteroids and minoxidil are used, with future research focusing on genetic and immune therapies.

Using patients' own fat-derived cells to treat alopecia areata significantly improved hair growth and was safe.

Black dots under trichoscopy can appear in different hair and scalp conditions, not just in alopecia areata.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Some babies are born with alopecia areata, and a treatment with clobetasol propionate can regrow hair in half of the cases.

Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Diphencyprone helped most patients with alopecia areata regrow some hair.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

The document concludes that ongoing research using animal models is crucial for better understanding and treating Alopecia Areata.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

The document concludes that more research is needed to understand and treat Beard Alopecia Areata due to limited current knowledge and evidence.

Laser and light therapies, especially the 308 nm excimer laser, are effective and safe for treating alopecia areata, but more research is needed.

Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.

Alopecia areata has a complex genetic basis that was not fully understood as of 2001.

The erbium-glass laser effectively promotes hair regrowth in alopecia areata.

Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.

Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.